ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
December 04, 2020Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ... -
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
January 17, 2019Ascletis Pharma Inc and Suzhou Alphamab Co., Ltd. (Alphamab) jointly announce today that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for ..... -
Ascletis Pharma to develop Alphamab’s viral diseases drug in China
January 16, 2019Ascletis Pharma has signed an exclusive licensing agreement with Suzhou Alphamab to develop an investigational candidate, KN035, for the treatment of viral diseases such as hepatitis B in Greater China....
Pharma Sources Insight January 2025
